Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study.
Holger N LodeKaroline EhlertStephanie HuberSascha Troschke-MeurerNikolai SiebertMaxi ZumpeHans LoibnerRuth Lydia LadensteinPublished in: British journal of cancer (2023)
The study is registered with ClinicalTrials.gov (NCT02743429) and EudraCT (2014-000588-42).